Icon and PAREXEL are involved in the clinical trials market landscape.

1 report, 1 independent Updated Jul 31

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

AbbVie Icon PAREXEL

Keep exploring

Part of

Thermo Fisher Scientific, Sharp Services LLC, and PAREXEL International lead the clinical trial supply market. All 1 developments

The entities involved

AbbVie
pharmaceutical company
- MarketBeat's screener has identified a list of dividend stocks.Sun 22:22
- AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Sun 13:48
Icon
2005 film directed by Charles Martin Smith

Nothing else this week.
PAREXEL
American biopharmaceutical company
- Parexel announced a transformation from Raleigh and appointed a new Managing Director in India.Wed 14:23

Related events

Syndax Pharmaceuticals and AbbVie are competing in the healthcare and biopharma sector.Sep 6

Coverage

Newest first; wire copies grouped

Jul 31GlobeNewswireSicca Syndrome (Sjogren) Clinical Trials Market Landscape Report 2025 Featuring Novartis, BMS, ICON, AbbVie, Parexel, Thermo Fisher Scientific, Amgen, Laboratory Corp of America, IQVIA, Syneos Health